Top executives weigh in at CIIE
A1: This is our third year at the CIIE, and this year we are proudly bringing more of our breakthrough innovations and new strategic partnerships to show the world how the patient-centric innovation embedded into the DNA of BMS can help Chinese patients fight serious diseases, and help China achieve the goals of its Healthy China vision.
China is a strategic and important market for BMS. The CIIE provides us with an excellent platform to catch vast and promising collaboration opportunities.
A2: China is an important engine of the global economy and we see the critical role China will play in helping the global economy recover from the impact of COVID-19.
We have seen in the past years the positive "carry-on effects" produced by the CIIE through promoting the economic development of China and the world.
This year, for the very first time, the Biomedicine Subsection will gather global innovations while also driving focus on more collaborations for open innovation. And the establishment of the Biomedical Committee will bring more "carry-on effects" and a dynamic momentum to the global biomedical innovation.
We would like to take advantage of the shared opportunities offered by the CIIE and the unique benefits of the Biomedical Committee to continue to work closely with the Chinese government and more local partners to support the development of "Healthy China 2030."
A3: China is driving the global economic recovery through its effort to increase imports. Take the healthcare industry as an example. China has accelerated the review and approval process for global innovative medicines in recent years, which not only benefits Chinese patients but also provides new impetus for the development and innovation of the global health industry.
BMS is making a long-term commitment to healthcare and innovation in China, as a key growth driver for BMS. In the next five years, our goal is to introduce in China up to 30 innovative medicines and indications from our diverse therapeutic areas. We are confident BMS will hit our goal with supportive Chinese government policy.
A4: China has become a vibrant player in the rapidly growing biomedical industry. In particular, with the guidance of the "dual circulation" strategy, China's biomedical industry will play a critical role in collaboration for open innovation, and in contribution to the achievement of Healthy China 2030 plan and the 14th Five-Year Plan.
China also has already become one of the top players globally in the contribution to pharmaceutical innovation.
BMS is committed to working with the government to foster innovation and economic growth.
A5: There is no doubt that China has been continuously improving its business environment and encouraging open innovation and collaboration. In healthcare, China has made significant progress in the last several years, expanding access to innovative medicines for its people, reforming its health system and elevating its regulations to meet international standards. Leveraging this, BMS has accelerated introduction of its innovative medicines to benefit patients in China. Our intended investment in China is also made with the growing supportive environment of the Chinese government. This makes me more confident in the future of our business in China.
A7: Based on our long-term commitment to the local market and the needs of industry development, we are very keen to see China will continue to deepen reform of its medical system, accelerate introducing global innovative medicines and build a multilayer health security system, ensuring a more attractive and open market environment for foreign bio-pharmaceutical companies.
